What is Alligator Bioscience?
Alligator Bioscience is a clinical-stage biotechnology firm headquartered in Lund, Sweden, dedicated to pioneering antibody-based pharmaceuticals for oncology. The company's core focus lies in developing tumor-directed immunotherapies, specifically agonistic mono- and bispecific antibodies. As a publicly traded entity on Nasdaq Stockholm (ATORX), Alligator Bioscience serves healthcare providers and research institutions engaged in advanced cancer treatment and investigation.
How much funding has Alligator Bioscience raised?
Alligator Bioscience has raised a total of $10M across 1 funding round:
Private Equity
$10M
Private Equity (2015): $10M, investors not publicly disclosed
What's next for Alligator Bioscience?
The recent major strategic investment signals a pivotal phase for Alligator Bioscience, likely enabling the acceleration of its clinical pipeline and the expansion of its research and development initiatives. This capital infusion is expected to bolster the company's efforts in advancing its novel immunotherapies through critical trial stages, potentially leading to significant breakthroughs in cancer treatment and solidifying its market position. The company's trajectory suggests a focus on scaling operations and forging strategic partnerships to maximize the therapeutic potential of its antibody-based pharmaceuticals.
See full Alligator Bioscience company page
